Agios Pharmaceuticals
AGIO
167 hedge funds and large institutions have $2.37B invested in Agios Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 84 increasing their positions, 34 reducing their positions, and 16 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 34
75% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 16
7% more funds holding
Funds holding: 156 → 167 (+11)
1% less capital invested
Capital invested by funds: $2.39B → $2.37B (-$19.4M)
1.34% less ownership
Funds ownership: 97.02% → 95.68% (-1.3%)
38% less call options, than puts
Call options by funds: $11.1M | Put options by funds: $17.9M
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$45.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$43.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$34.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.6M |
| 5 |
BlackRock
New York
|
+$26M |
Top Sellers
AGIO Hedge Fund Activity: Q2 2017 in Review
167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2017, worth a combined $2.37B — down 0.81% from $2.39B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AGIO positions and 16 closed out — a net gain of 12 holders — while 84 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $45.8M. The largest seller was Flagship Pioneering, exiting entirely with an estimated $56.4M sold.
- 167 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2017, up from 156 in Q1 2017.
- Funds reported $2.37B of Agios Pharmaceuticals stock for Q2 2017, down 0.81% quarter-over-quarter.
- 28 funds opened new Agios Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of +12 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2017 was Fidelity Investments, an estimated $45.8M added.
- The largest Agios Pharmaceuticals seller in Q2 2017 was Flagship Pioneering, an estimated $56.4M sold.
Based on aggregated 13F filings for Q2 2017.